Tracking safety of iruplinalkib for alk-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study follows people with alk-positive non-small cell lung cancer who are taking iruplinalkib to see how well it works and how safe it is in real life. It helps doctors learn more about the drug's effects outside of clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that is locally advanced or has spread, and it is alk-positive.
- You are currently taking iruplinalkib, or you are about to start it as your first treatment for this cancer.
- You had a chest and abdominal CT scan and a brain MRI within 42 days before your first dose.
- You had routine blood and biochemistry tests within 30 days before your first dose.
- You have not taken any other alk-targeted therapy before, except possibly as part of surgery or radiation before your main treatment.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a pill called iruplinalkib after surgery for early-stage ALK-positive lung cancer can help keep cancer from coming back. Iruplinalkib is a type of targeted therapy that blocks cancer cells with a specific ALK gene change.
This study tests a combination of two targeted medicines for people with a specific type of non-small cell lung cancer (NSCLC) that has the ALK gene change. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
This trial tests a targeted therapy pill (called iruplinalkib) given before surgery for people with a certain type of lung cancer (ALK-positive NSCLC). The goal is to see if the pill can shrink the tumor, making it easier to remove completely during surgery.
This study tests whether giving a new targeted pill (iruplaltinib) along with chemotherapy before surgery can help shrink tumors and improve outcomes for people with ALK-positive lung cancer. Participation involves taking study drugs, having tests, and then undergoing surgery.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.